Views: 1,307 | Downloads:
17
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Detection of Molecular Variants of BCR-ABL Gene in Bone Marrow and Blood of Patients with Chronic Myeloid Leukemia by Reverse-Transcriptase Polymerase Chain Reaction (RT -PCR)
UdomsakdiAuewarakul C 
,
UPratya Y ,
Boonmoh S ,
Vatanavicharn S
,
UPratya Y ,
Boonmoh S ,
Vatanavicharn S Very limited data exists in Thailand regarding the frequency of BCR-ABL leukemic
gene and its prognostic implication in Thai CML patients. The objective of this study was to develop
a rapid molecular assay for the detection of the two most commonly reported variants of BCR-ABL
fusion gene, B2A2 and B3A2 in CML patients. Bone marrow or peripheral blood were used for
RNA extraction and reverse-transcribed to eDNA for PCR amplification. 92 per cent of CML
patients (91199) were positive for BCR-ABL gene (61% B3A2 and
3lo/c
B2A2). 8/99 CML
patients were BCR-ABL-negative. B3A2 and B2A2-positive patients did not have any different
clinical and hematological features at presentation although B3A2 patients tended to be slightly
older and had higher platelet counts. 71171 non-CML including other MPD and leukemia cases
were all negative for BCR-ABL gene. In conclusion, a rapid RT-PCR assay has now been deve-
loped for the detection of this hallmark gene in CML patients. It should be of great value in the
differential diagnosis of CML from other diseases. Long-term follow-ups of CML patients with
different variants are needed to determine the prognostic importance of each gene variant.
Key word : BCR-ABL Gene Variant, Chronic Myeloid Leukemia
gene and its prognostic implication in Thai CML patients. The objective of this study was to develop
a rapid molecular assay for the detection of the two most commonly reported variants of BCR-ABL
fusion gene, B2A2 and B3A2 in CML patients. Bone marrow or peripheral blood were used for
RNA extraction and reverse-transcribed to eDNA for PCR amplification. 92 per cent of CML
patients (91199) were positive for BCR-ABL gene (61% B3A2 and
3lo/c
B2A2). 8/99 CML
patients were BCR-ABL-negative. B3A2 and B2A2-positive patients did not have any different
clinical and hematological features at presentation although B3A2 patients tended to be slightly
older and had higher platelet counts. 71171 non-CML including other MPD and leukemia cases
were all negative for BCR-ABL gene. In conclusion, a rapid RT-PCR assay has now been deve-
loped for the detection of this hallmark gene in CML patients. It should be of great value in the
differential diagnosis of CML from other diseases. Long-term follow-ups of CML patients with
different variants are needed to determine the prognostic importance of each gene variant.
Key word : BCR-ABL Gene Variant, Chronic Myeloid Leukemia
Download:
PDF